Spots Global Cancer Trial Database for Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
Official Title: A Phase II, Prospective, Multicenter Study Ofrelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
Study ID: NCT05381506
Conditions
Interventions
Study Description
Brief Summary: This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Guangxi Medical University Cancer Hospital, Naning, Guangxi, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
West China Hospital.Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Zhiming Li, Dr.
Affiliation: Sun Yat-sen University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
